On the pharmacotherapy of obsessive-compulsive disorder: Is a consensus possible?

Canadian Journal of Psychiatry

Volumn 45, Issue 3, 2000, Pages 257-262

  Todorov, Christo ^a,b   Freeston, Mark H ^a,b   Borgeat, Francois ^b,c  

^a CENTRE DE RECHERCHE FERNAND SEGUIN   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Clomipramine; Expert consensus guidelines; Obsessive compulsive disorder; Placebo; Selective serotonin reuptake inhibitors

Indexed keywords

CLOMIPRAMINE; FLUOXETINE; FLUVOXAMINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; MULTICENTER STUDY; OBSESSION; PRACTICE GUIDELINE; REVIEW; TREATMENT OUTCOME;

EID: 0034079873     PISSN: 07067437     EISSN: None     Source Type: Journal    
DOI: 10.1177/070674370004500304     Document Type: Review

References (26)

1. Expert Consensus Guideline Series. Treatment of Obsessive-Compulsive Disorder. J Clin Psychiatry 1997;58 Suppl:3S-72S.
2. Fineberg N. Refining treatment approaches in obsessive-compulsive disorder. Int Clin Psychopharmacol 1996;11 Suppl:13S-22S.
3. Flament MF, Bisserbe JC. Pharmacologic treatment of Obsessive-Compulsive Disorder: Comparative Studies. J Clin Psychiatry 1997;58 Suppl 12:18S-22S.
4. Greist JH, Jefferson JW, Kobak KA, Katzelnik DJ, Serlin RC. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder: a meta-analysis. Arch Gen Psychiatry 1995;52:53-60.
5. Stein DJ, Spadaccini E, Hollander E. Meta-analysis of pharmacotherapy trials for obsessive-compulsive disorder. Int Clin Psychopharmacol 1995;10:11-8.
6. Piccinelli M, Pini S, Bellantuono C, Willkinson G. Efficacy of drug treatment in obsessive-compulsive disorder: a meta-analytic review. Br J Psychiatry 1995;166:424-43.
7. Cox BJ, Swinson RP, Morrison B, Lee PS. Clomipramine, fluoxetine, and behaviour therapy in the treatment of obsessive-compulsive disorder: a meta-analysis. J Behav Ther Exp Psychiatry 1993;24:149-53.
8. Bisserbe JC, Lane RM, Flament MF, and the Franco-Belgian OCD Study Group. A double-blind comparison of sertraline and clomipramine in outpatients with obsessive-compulsive disorder. J Assn Eur Psychiatrists 1997;12:82-93.
9. Rasmussen SA. The Meta-analytic Saga of Serotonin Reuptake Inhibitors in an Obsessional Word. CNS Spectrums, 1996;1,2:9
10. Pigott TA, Pato MT, Bernstein SE, Grover GN, Hill JL, Tolliver TJ, and others. Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 1990;47:926-32.
11. Lopez-Ibor J Jr, Saiz J, Cottraux J, Note Ẏ, Viñas R, Bourgeois M, and others. Double-blind comparison of fluoxetine versus clomipramine in the treatment of obsessive-compulsive disorder. Eur Neuropsychopharmacol 1996;6:111-8
12. Todorov C, Brassard M, Fontaine R, Vezina M, Elie R. Fluoxetine versus clomipramine in obsessive-compulsive disorder. Tenth World Congress of Psychiatry; 1996 August 23-28; Madrid. Abstracts 2:296.
13. Smeraldi E, Erzegovesi S, Bianchi Ẏ, Pasquali L, Gocchi S, Ronchi P. Fluvoxamine vs clomopramine treatment in obsessive-compulsive disorder: a preliminary study. New Trends Exp Clin Psychiatry. 1992;8:63-5.
14. Freeman C, Trimble MR, Deakin JFW, Stokes TM, Ashford JJ. Fluvoxamine versus Clomipramine in the treatment of obsessive-compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison. J Clin Psychiatry 1994;55:301-5.
15. Koran LM, McElroy SL, Davidson JRT, Rasmussen SA, Hollander E, Jenike MA. Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a double-blind comparison. J Clin Psychopharmacol 1996;16:121-9.
16. Kelly A. Selecting a serotonin reuptake inhibitor for obsessive-compulsive disorder. CNS Spectrums 1996;1:32-8.
17. Zohar J, Judge R, and the OCD Paroxetine Study Investigators. Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. Br J Psychiatry 1996;169:468-74.
18. Leonard HL. New developments in the treatment of Obsessive-Compulsive Disorder. J Clin Psychiatry, 1997;58 Suppl 14:39S-45S.
19. Greist J, Chouinard G, Duboff E, Halaris A, Kim SW, Koran L, and others. Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch Gen Psychiatry 1995;52:289-95.
20. Mavissakalian MR, Jones B, Olson S. Absence of placebo response in obsessive-compulsive disorder. J Nerv Ment Dis 1990;4:268-70.
21. Clomipramine in the treatment of patients with obsessive-compulsive disorder. The Clomipramine Collaborative Study Group. Arch Gen Psychiatry 1991; 48:730-8.
22. Pigott TA. OCD: Where the serotonin selectivity story begins. J Clin Psychiatry 1996;57 Suppl:11S-20S.
23. Strauss JL, Cavanaugh S. Placebo effects: Issues for clinical practice in psychiatry and medicine. Psychosomatics 1996;37:315-26.
24. Stahl, SM. Not so selective serotonin uptake inhibitors. J Clin Psychiatry 1998; 59:343-4.
25. Murphy DL, Andrews AM, Wichems CH, Qian L, Michihisa T, Greenberg B. Brain serotonin neurotransmission: An overview and update with an emphasis on serotonin subsystem heterogeneity, multiple receptors, interactions with other neurotransmitter systems and consequent implications for understanding the actions of serotonergic drugs. J Clin Psychiatry 1998;59 Suppl 15:4-12.
26. Trindade E, Menon D. Selective serotonin reuptake inhibitors SSRIs) for major depression. Part I. Evaluation of the clinical literature. Ottawa: Canadian Coordinating Office for Health Technology Assessment; 1997. Aug. Report 3E.